Contrasting Delcath Systems (NASDAQ:DCTH) & ADB International Group (OTCMKTS:EQUR)

Delcath Systems (NASDAQ:DCTH) and ADB International Group (OTCMKTS:EQUR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Profitability

This table compares Delcath Systems and ADB International Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delcath Systems	3.17%	2.63%	2.39%
ADB International Group	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Delcath Systems and ADB International Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1	0	5	0	2.67
ADB International Group	0	0	0	0	0.00

Delcath Systems presently has a consensus price target of $22.50, indicating a potential upside of 148.07%. Given Delcath Systems’ stronger consensus rating and higher possible upside, analysts plainly believe Delcath Systems is more favorable than ADB International Group.

Earnings & Valuation

This table compares Delcath Systems and ADB International Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23 million	3.70	$2.70 million	$0.07	129.57
ADB International Group	N/A	N/A	N/A	N/A	N/A

Delcath Systems has higher revenue and earnings than ADB International Group.

Insider and Institutional Ownership

61.1% of Delcath Systems shares are owned by institutional investors. 17.9% of Delcath Systems shares are owned by company insiders. Comparatively, 79.6% of ADB International Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Delcath Systems beats ADB International Group on 8 of the 9 factors compared between the two stocks.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

About ADB International Group

E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices. Its BST devices implement patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The company was incorporated in 1988 and is based in New York, New York.